[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356745-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356745-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","global-analysis-of-cancer-cell-responses-to-usp9x-inhibition","Global analysis of cancer cell responses to USP9X inhibition","","The ubiquitin-specific protease USP9X functions as a deubiquitinase with context-dependent roles in cancer, acting as either oncogene or tumour suppressor, while its therapeutic value remains uncertain. The study characterizes WEHI-092, a piperazine-based USP9X-specific inhibitor that binds a distinct region in the USP9X Fingers subdomain. Proteomics and ubiquitinomics show USP9X regulates different substrates than USP7, with a cell-line dependent substrate profile, including 17 commonly controlled proteins as proximal biomarkers. WEHI-092 arrests the cell cycle at metaphase without inducing cell death, supporting growth suppression and positioning USP9X inhibitors as selective mitotic poisons.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/global-analysis-of-cancer-cell-responses-to-usp9x-inhibition/356745/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/global-analysis-of-cancer-cell-responses-to-usp9x-inhibition/356745.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is USP9X and why is it relevant to cancer therapy?","Question",{"text":63,"@type":64},"USP9X is a human deubiquitinase whose role in cancer can vary by context, acting as an oncogene or a tumour suppressor. Its usefulness as a cancer target has been unclear, motivating the study.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does WEHI-092 inhibit USP9X?",{"text":68,"@type":64},"WEHI-092 is a piperazine-based, USP9X-specific small-molecule inhibitor. It binds to a unique region in the USP9X Fingers subdomain, distinct from known DUB-inhibitor binding sites.",{"name":70,"@type":61,"acceptedAnswer":71},"What cellular effects does WEHI-092 produce in cancer cells?",{"text":72,"@type":64},"In unrelated cell lines, WEHI-092 treatment arrests the cell cycle in metaphase without inducing cell death. This aligns with growth suppression observed in long-term clonogenic assays and supports a mitotic poison mechanism.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356745,1791204710,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Resource  \nGlobal analysis of cancer cell responses to USP9X inhibition  \nPhilipp Schenk 1,2, Shane M Devine 1,2, Simon A Cobbold 1,2, Niall D Geoghegan1,2,  \nElizabeth L Kyran1,3,4, Ching-Seng Ang5, Jack A Alexandrovics1,2, Dale J Calleja 1,2, Dylan H Multari 1,2, Vineet Vaibhav1,2, Bernadine G C Lu 1,2, Theresa A Klemm 1,2, Laura F Dagley1,2, Kym N Lowes1,2, Nicholas A Williamson 5, Pieter J A Eichhorn 6,7, Ashley P Ng 1,2,8,9, Rebecca Feltham 1,2 & David Komander 1,2 ✉  \nAbstract  \nThe ubiquitin-speciﬁc protease (USP) USP9X is a human deubiquitinase (DUB) with a large number of described targets and cellular roles. In cancer, USP9X is found as an oncogene or as a tumour suppressor depending on context, and its utility as a target for cancer therapy remains unclear. We here describe WEHI-092, a piperazine-based USP9X-speciﬁc small-molecule inhibitor, which binds to a unique region in the USP9X Fingers-subdomain, distinct from known DUB-inhibitor binding sites. Using proteomics and ubiquitinomics, we show that USP9X targets distinct substrates compared to USP7, yet the substrate proﬁle of USP9X varies signiﬁcantly across cancer cell lines. We reveal a core set of 17 proteins commonly regulated by USP9X in most cell lines, which we consider as proximal biomarkers for USP9X inhibition. Consistent with proteomics, we show in unrelated cell lines that WEHI-092 treatment arrests the cell cycle in metaphase without inducing cell death. This explains growth suppression in long-term clonogenicassays in most cancer cell lines, and positions USP9X inhibitors asa new class of selective mitotic poisons.  \nKeywords USP9X; DUB Inhibitor; Cancer; Ubiquitinomics; Substrate Identiﬁcation  \nSubject Categories Pharmacology & Drug Discovery; Post-translational Modiﬁcations & Proteolysis  \n[https://doi.org/10.1038/s44318-026-00742-y](https://doi.org/10.1038/s44318-026-00742-y)  \nReceived 9 June 2025; Revised 9 February 2026; Accepted 20 February 2026  \nPublished online: 7 April 2026  \nIntroduction  \nProtein ubiquitination is a key regulator of protein homeostasis, and as such has many recognised roles in human disease settings, in particular cancer (Deng et al, 2020) . The attachment of ubiquitin to  \nproteins most commonly triggers their degradation through the ubiquitin proteasome system (UPS), which facilitates the clearance of old and damaged proteins but can also regulate cellular cascades such as the cell cycle (Hershko, 1997) . Overall, more than 5% of the human genome encodes for proteins that attach, bind, or remove avast array of distinct and dynamic ubiquitin modiﬁcations (Agrata and Komander, 2025) . Within these proteins, more than 700 E3 ligases facilitate ubiquitination in conjunction with E1 activating and E2 conjugating enzymes, while ~100 deubiquitinases (DUBs) remove ubiquitin signals from proteins (Clague et al, 2019) .  \nMany oncogenes are under the control of the UPS, and are ubiquitinated and degraded, often in a highly regulated fashion. The UPS is exploited pharmacologically, most prominently via targeted protein degradation (TPD) approaches using proteolysistargeting chimeras (PROTACs) or molecular glues (Békés et al, 2022; Zhao et al, 2022) . Some of the most desired cancer targets, however, remain undruggable due to a lack of efﬁcacious smallmolecule binders. An orthogonal way to drive an oncoprotein towards degradation can be achieved through inhibition of the DUB that stabilises the oncoprotein (Harrigan et al, 2018) . Indeed, hundreds of papers report deregulated DUB activity in cancer, where DUB deregulation stabilises oncoproteins ordestabilises tumour suppressors (Dewson et al, 2023) . Hence, DUB inhibitors provide an orthogonal strategy to induce oncoprotein degradation.  \nUbiquitin-speciﬁc protease (USP) DUBs have received most pharmacological attention. USP DUBs are typically promiscuous regarding the ubiquitin signals they remove but achieve targetspeciﬁcity via substrate-binding domains (Mevissen and Komande","cbCaitKhFkALnc6H","https://ap.wps.com/l/cbCaitKhFkALnc6H","pdf",11326475,26,"English","# Abstract\n# Introduction\n## Ubiquitination and the ubiquitin proteasome system (UPS)\n## DUB inhibition as an orthogonal cancer strategy\n## Pharmacological focus on USP DUBs\n# USP9X background and relevance to cancer","[{\"question\":\"What is USP9X and why is it relevant to cancer therapy?\",\"answer\":\"USP9X is a human deubiquitinase whose role in cancer can vary by context, acting as an oncogene or a tumour suppressor. Its usefulness as a cancer target has been unclear, motivating the study.\"},{\"question\":\"How does WEHI-092 inhibit USP9X?\",\"answer\":\"WEHI-092 is a piperazine-based, USP9X-specific small-molecule inhibitor. It binds to a unique region in the USP9X Fingers subdomain, distinct from known DUB-inhibitor binding sites.\"},{\"question\":\"What cellular effects does WEHI-092 produce in cancer cells?\",\"answer\":\"In unrelated cell lines, WEHI-092 treatment arrests the cell cycle in metaphase without inducing cell death. This aligns with growth suppression observed in long-term clonogenic assays and supports a mitotic poison mechanism.\"}]","Global analysis of cancer cell responses to USP9X inhibition | PDF",1790127082,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59a7e41828d9b8cbf16e32248145ace7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8cee2d8b538ba8ad2d331eeb4acb57c.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aed739fe5f90976ce4440d62978df196.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d742876fb4972abbf5a2b5d8469eb0f9.webp",980,1301]